Actively Recruiting

Phase 1
Age: 19Years +
All Genders
NCT06320990

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Led by University of Nebraska · Updated on 2026-05-14

15

Participants Needed

1

Research Sites

222 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Pancreatic mucinous cystic neoplasm (MCN) is a precursor to invasive pancreatic adenocarcinoma which occurs almost exclusively in females in their 5th-7th decade. Currently the only option for MCN treatment and prevention of invasive pancreatic ductal adenocarcinoma (PDA) is oncologic resection. The clinical features of pancreatic MCN support the influence of sex hormones in the pathogenesis of the disease. Anti-hormonal therapy may therefore constitute an effective approach to treatment. Preliminary analyses from preclinical studies suggest that tamoxifen inhibits the spread and normal life cycle in MCN epithelial cells and fibroblasts. Investigators hypothesize that in humans, treatment with tamoxifen will lead to cyst regression or stabilization and may spare or delay the need for resection. Up to 15 participants not undergoing immediate resection will be enrolled and take tamoxifen orally for up to 24 weeks. The study will assess the feasibility of tamoxifen as a treatment for pancreatic MCN.

CONDITIONS

Official Title

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 63; 19 years
  • Clinically diagnosed pre-invasive pancreatic mucinous cystic neoplasm (MCN), measurable by cross-sectional imaging
  • No planned surgical removal of the cyst due to cyst features, patient factors, or preference
  • Females of reproductive potential and males with partners of reproductive potential must use two contraception methods during the study and for 3 months after treatment; non-child-bearing potential defined as age 45 or older with no menses for 63; 12 months or surgical removal of uterus and/or ovaries
  • Estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73m2
  • Willing and able to provide informed consent and follow the study protocol
Not Eligible

You will not qualify if you...

  • Presence of invasive pancreatic adenocarcinoma or high-grade dysplasia
  • Presence of solid component or mural nodule, main pancreatic duct dilation or abrupt change, obstructive jaundice, lymphadenopathy
  • Current or prior use of tamoxifen or other estrogen antagonists within 5 years
  • Current or planned use of hormonal treatments including estrogen, progesterone, androgens, hormone replacement therapy, or hormonal contraceptives except levonorgestrel-releasing IUD
  • Pregnancy or nursing
  • Known allergy or sensitivity to tamoxifen
  • Symptomatic cataracts or retinopathy affecting vision
  • Current use of warfarin
  • History of deep vein thrombosis, pulmonary embolism, or high risk of blood clots
  • History of stroke
  • Known endometrial hyperplasia or personal history of endometrial carcinoma, uterine sarcoma, or uterine carcinosarcoma
  • History of intestinal disease or major stomach surgery affecting tamoxifen absorption or inability to swallow pills
  • Uncontrolled illness including active infections, serious heart problems, or other conditions that affect safety or treatment tolerance
  • Planned elective surgery during the study
  • Participation in another clinical trial with investigational treatment within 28 days
  • Any condition making the participant unsuitable or unlikely to follow study procedures or treatment requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198

Actively Recruiting

Loading map...

Research Team

M

Mahdi Hassan, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here